Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias
NCT: NCT07793630 · NOT_YET_RECRUITING
Brief Summary
his prospective, randomized, controlled, intraindividual split-leg clinical trial will compare isolated polidocanol foam sclerotherapy with the Laser After Foam (LAAF) technique for the treatment of reticular veins and telangiectasias of the lower limbs. The study will include 70 women aged 18 to 60 years with bilateral CEAP C1 telangiectasias and/or reticular veins. Each participant will receive LAAF in one lower limb and isolated foam sclerotherapy in the contralateral limb, with treatment laterality determined by randomization. The study will evaluate vascular clearance, residual vascular area, hyperpigmentation, retained thrombi and need for drainage, pain, adverse events, aesthetic improvement, patient satisfaction, and quality of life during follow-up through 180 days.
Frequently Asked Questions
What is Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias?
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias is a clinical trial registered under NCT07793630. Current status: NOT_YET_RECRUITING.
What is the status of NCT07793630?
The current status of NCT07793630 (Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias) is: NOT_YET_RECRUITING.
When did Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias start?
Foam Sclerotherapy With or Without Transdermal Laser for Reticular Veins and Telangiectasias started on 2026-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.